Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma.

Publication Type:

Journal Article

Authors:

Graf, S A; Stevenson, P A; Holmberg, L A; Till, B G; Press, O W; Chauncey, T R; Smith, S D; Philip, M; Orozco, J J; Shustov, A R; Green, D J; Libby, E N; Bensinger, W I; Pagel, J M; Maloney, D G; Zhou, Y; Cassaday, R D; Gopal, A K

Source:

Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, Volume 26, Issue 11, p.2323-8 (2015)

Keywords:

Biologics Production Core Facility, Research Trials Office Core Facility - Biostatistics Service, Specimen Processing Core Facility

Abstract:

High dose therapy and autologous stem cell transplantation (ASCT) improves outcomes for patients with mantle cell lymphoma (MCL), but relapse ultimately occurs in most patients. Recently presented interim results from a phase III prospective trial suggest maintenance rituximab (MR) after ASCT for MCL improves progression-free survival (PFS). The maturation of these data and any benefit of MR on overall survival (OS) remain to be defined.